Rein Therapeutics, Inc. (RNTX)
↓ Download CSV- Sector Manufacturing
- Fiscal year ends Dec 31
In fiscal 2025, Rein Therapeutics, Inc. reported revenue of $0. The company ran a net loss. It held $24.16M in total assets against $7.24M in total liabilities.
Key ratios (FY2025)
-294.8%
Return on equity
| Metric (FY) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | — |
| Operating Income | -$50.63M | -$65.11M | -$16.28M | -$27.65M | -$26.61M | -$20.50M | -$29.96M | -$31.90M | -$23.01M | -$18.17M |
| Net Income | -$49.87M | -$62.88M | -$15.73M | -$27.33M | -$26.16M | -$27.33M | -$29.37M | -$31.55M | -$22.60M | -$18.12M |
| EPS (Diluted) | $-1.96 | $-3.51 | $-3.42 | $-6.02 | $-5.89 | — | — | — | — | — |
| Total Assets | $24.16M | $62.19M | $106.01M | $22.01M | $48.48M | $16.34M | $26.47M | $30.31M | $52.69M | $22.02M |
| Total Liabilities | $7.24M | $7.80M | $7.71M | $3.38M | $4.58M | $4.18M | $10.43M | $10.71M | $4.89M | $4.08M |
| Shareholders' Equity | $16.92M | $54.39M | $98.30M | $18.62M | $43.90M | $12.16M | $16.05M | $19.60M | $47.80M | -$111.81M |
| Cash & Equivalents | $3.21M | $12.87M | $17.34M | $5.19M | $3.60M | $7.05M | $5.31M | $10.63M | $11.86M | $20.71M |
| Operating Cash Flow | -$19.36M | -$22.29M | -$19.81M | -$24.86M | -$23.75M | -$20.48M | -$26.47M | -$27.93M | -$20.53M | — |
| Capital Expenditures | — | — | — | — | $157.0K | $5.0K | $151.0K | $4.42M | $142.0K | — |
| Shares Outstanding | 27.55M | 21.67M | 4.89M | 4.54M | 4.53M | 43.80M | 27.81M | 14.75M | 14.72M | 432.4K |
| Dividends Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |